At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
ADXS-503 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating ADXS-503 and Pembrolizumab for Lung Cancer, Non-Small Cell and 2 related conditions. Completed, enrolled 24 participants across 9 sites.
Detailed Summary
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedFeb 2019
Primary CompletionFeb 2022
TodayJul 2026
First PostedFeb 20, 2019
Enrollment StartFeb 12, 2019
Primary CompletionFeb 22, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 7.4 years ago
Interventions
ADXS-503drug
A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
Pembrolizumabdrug
a programmed death receptor-1 (PD-1)- blocking antibody.